

Elfriede Bollschweiler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8350566/publications.pdf>

Version: 2024-02-01

47
papers

2,263
citations

257450

24
h-index

265206

42
g-index

48
all docs

48
docs citations

48
times ranked

2633
citing authors

#	ARTICLE	IF	CITATIONS
1	Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. <i>Cancer</i> , 2001, 92, 549-555.	4.1	430
2	Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer. <i>Annals of Surgery</i> , 2005, 242, 684-692.	4.2	334
3	Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. <i>World Journal of Gastroenterology</i> , 2014, 20, 5679.	3.3	143
4	Staging of esophageal carcinoma: Length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?. <i>Journal of Surgical Oncology</i> , 2006, 94, 355-363.	1.7	137
5	Improving Informed Consent of Surgical Patients Using a Multimedia-Based Program?. <i>Annals of Surgery</i> , 2008, 248, 205-211.	4.2	102
6	Current and future treatment options for esophageal cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1001-1010.	1.8	102
7	What Should Be the Gold Standard for the Surgical Component in the Treatment of Locally Advanced Esophageal Cancer. <i>Annals of Surgery</i> , 2014, 260, 1016-1022.	4.2	93
8	Vitamin intake and risk of subtypes of esophageal cancer in Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 575-580.	2.5	82
9	Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 132-138.	3.8	64
10	Treatment of early gastric cancer in the Western World. <i>World Journal of Gastroenterology</i> , 2014, 20, 5672.	3.3	58
11	Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. <i>Future Oncology</i> , 2010, 6, 25-35.	2.4	49
12	Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. <i>Gastric Cancer</i> , 2017, 20, 83-91.	5.3	48
13	Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. <i>Langenbeck's Archives of Surgery</i> , 2003, 388, 239-244.	1.9	47
14	Prognostic Significance of a New Grading System of Lymph Node Morphology After Neoadjuvant Radiochemotherapy for Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2011, 92, 2020-2027.	1.3	45
15	Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 3187-3194.	1.5	44
16	Prevalence of Dysphagia in Patients with Gastroesophageal Reflux in Germany. <i>Dysphagia</i> , 2008, 23, 172-176.	1.8	42
17	Gastric Outlet Obstruction After Esophagectomy: Retrospective Analysis of the Effectiveness and Safety of Postoperative Endoscopic Pyloric Dilatation. <i>World Journal of Surgery</i> , 2016, 40, 2405-2411.	1.6	39
18	Total minimally invasive esophagectomy for esophageal adenocarcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 4957-4965.	2.4	37

#	ARTICLE	IF	CITATIONS
19	Both GLUT-1 and GLUT-14 are Independent Prognostic Factors in Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 822-831.	1.5	36
20	Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer – A propensity score matched analysis. <i>European Journal of Cancer</i> , 2014, 50, 2950-2957.	2.8	34
21	Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 549-558.	0.6	33
22	Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. <i>Journal of Clinical Pathology</i> , 2016, 69, 956-961.	2.0	30
23	Evaluation of POSSUM scoring system in patients with gastric cancer undergoing D2-gastrectomy. <i>BMC Surgery</i> , 2005, 5, 8.	1.3	29
24	Supportive evidence for <i>FOXP1</i> , <i>BARX1</i> , and <i>FOXF1</i> as genetic risk loci for the development of esophageal adenocarcinoma. <i>Cancer Medicine</i> , 2015, 4, 1700-1704.	2.8	26
25	The Barrett's-associated variants at <i>GDF7</i> and <i>TBX5</i> also increase esophageal adenocarcinoma risk. <i>Cancer Medicine</i> , 2016, 5, 888-891.	2.8	21
26	Bile Reflux into the Stomach and the Esophagus for Volunteers Older than 40 Years. <i>Digestion</i> , 2005, 71, 65-71.	2.3	20
27	Neoadjuvant chemoradiation for patients with advanced esophageal cancer – which response grading system best impacts prognostic discrimination?. <i>Histopathology</i> , 2019, 74, 731-743.	2.9	20
28	High Prevalence of Colonic Polyps in White Males with Esophageal Adenocarcinoma. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 299-304.	1.3	19
29	Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 221-30.	2.2	16
30	High protein and mRNA expression levels of TUBB3 (class III β -tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 115179-115189.	1.8	13
31	Prognostic relevance of nutritional status in patients with advanced esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 275-278.	2.4	12
32	Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in esophageal adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 12113.	3.3	12
33	Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for Glut-1 and Hif-1 alpha. <i>Anticancer Research</i> , 2014, 34, 3313-20.	1.1	9
34	Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 225-228.	1.0	7
35	Molecular markers predicting lymph node metastasis in early esophageal cancer. <i>Histology and Histopathology</i> , 2015, 30, 1193-202.	0.7	7
36	External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 1250-1258.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Propensity scoreâ€“matched comparison between open and minimal invasive hybrid esophagectomy for esophageal adenocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 521-532.	1.9	6
38	Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus--Differences in Etiology, Epidemiology and Prevention. <i>Chinese-German Journal of Clinical Oncology</i> , 2004, 3, 201-204.	0.1	3
39	Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S228-S228.	1.7	3
40	Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by <i>ERCC1</i> or <i>ABC1</i> . <i>Future Oncology</i> , 2020, 16, 2075-2087.	2.4	2
41	Prognostic impact of blood biomarkers TS and DPD in neoadjuvant-treated esophageal cancer patients. <i>Anticancer Research</i> , 2015, 35, 1297-302.	1.1	2
42	Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients. <i>World Journal of Gastroenterology</i> , 2020, 26, 3236-3248.	3.3	1
43	Impact of a Hospital's Workload on Clinical Outcome after Resection for Carcinoma of the Esophagus. <i>Chinese-German Journal of Clinical Oncology</i> , 2004, 3, 244-248.	0.1	0
44	Invited Commentary. <i>Annals of Thoracic Surgery</i> , 2012, 93, 428.	1.3	0
45	Reply to the Comment on: HÃ¶lscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer â€“ A propensity score matched analysis. <i>Eur J Cancer</i> . 2014;50(17):2950â€“7. <i>European Journal of Cancer</i> , 2015, 51, 2097-2098.	2.8	0
46	Comment on â€œIs Local Endoscopic Resection a Viable Therapeutic Option for Early Clinical Stage T1a and T1b Esophageal Adenocarcinoma? A Propensity-matched Analysisâ€“. <i>Annals of Surgery</i> , 2021, 274, e916-e917.	4.2	0
47	GLUT-1 and GLUT-14 as independent prognostic factors in gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15064-e15064.	1.6	0